Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 28, 2015 07:15 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Observes Rare Disease Day

CAMBRIDGE, Mass., Feb. 28, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
February 26, 2015 16:10 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results

- Company records $158.4 million in net product sales of JUXTAPID® in 2014, representing 226% growth over 2013 - - Company generates $17.9 million in positive cash flow from operations in the...
February 25, 2015 16:10 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Presentation at the Cowen and Company Healthcare Conference

CAMBRIDGE, Mass., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
February 12, 2015 07:55 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals to Announce Fourth-Quarter and Full-Year 2014 Financial Results on Thursday, February 26

CAMBRIDGE, Mass., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
February 10, 2015 16:45 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

CAMBRIDGE, Mass., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
February 05, 2015 16:10 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
January 13, 2015 20:30 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

CAMBRIDGE, Mass., Jan. 13, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
January 12, 2015 07:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Reports Preliminary 2014 Net Product Sales, Its Outlook for 2015 and Other Business Updates

- Company Completes Acquisition of MYALEPT® - 2014 Total Net Product Sales Expected to be Between $156 and $158 Million, Representing Approximately 220 Percent Growth over 2013 - 2015...
January 12, 2015 07:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Completes Acquisition of MYALEPT(R)

CAMBRIDGE, Mass., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced that it has completed the acquisition of MYALEPT® (metreleptin) for injection, an...
January 05, 2015 16:05 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...